Literature DB >> 23908683

Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification.

Rohit Mehra1, Saravana M Dhanasekaran, Nallasivam Palanisamy, Pankaj Vats, Xuhong Cao, Jung H Kim, David Sl Kim, Timothy Johnson, Douglas R Fullen, Arul M Chinnaiyan.   

Abstract

E26 transformation-specific (ETS) transcription factors are known to be involved in gene aberrations in various malignancies including prostate cancer; however, their role in melanoma oncogenesis has yet to be fully explored. We have completed a comprehensive fluorescence in situ hybridization (FISH)-based screen for all 27 members of the ETS transcription factor family on two melanoma tissue microarrays, representing 223 melanomas, 10 nevi, and 5 normal skin tissues. None of the melanoma cases demonstrated ETS fusions; however, 6 of 114 (5.3%) melanomas were amplified for ETV1 using a break-apart FISH probe. For the six positive cases, locus-controlled FISH probes revealed that two of six cases were amplified for the ETV1 region, whereas four cases showed copy gains of the entire chromosome 7. The remaining 26 ETS family members showed no chromosomal aberrations by FISH. Quantitative polymerase chain reaction showed an average 3.4-fold (P value = .00218) increased expression of ETV1 in melanomas, including the FISH ETV1-amplified cases, when compared to other malignancies (prostate, breast, and bladder carcinomas). These data suggest that a subset of melanomas overexpresses ETV1 and amplification of ETV1 may be one mechanism for achieving high gene expression.

Entities:  

Year:  2013        PMID: 23908683      PMCID: PMC3730015          DOI: 10.1593/tlo.13340

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  31 in total

Review 1.  Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Authors:  Sook Ryun Park; Alice Chen
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

2.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Authors:  J Chad Brenner; Bushra Ateeq; Yong Li; Anastasia K Yocum; Qi Cao; Irfan A Asangani; Sonam Patel; Xiaoju Wang; Hallie Liang; Jindan Yu; Nallasivam Palanisamy; Javed Siddiqui; Wei Yan; Xuhong Cao; Rohit Mehra; Aaron Sabolch; Venkatesha Basrur; Robert J Lonigro; Jun Yang; Scott A Tomlins; Christopher A Maher; Kojo S J Elenitoba-Johnson; Maha Hussain; Nora M Navone; Kenneth J Pienta; Sooryanarayana Varambally; Felix Y Feng; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

Review 3.  Targeted therapy in GIST: in silico modeling for prediction of resistance.

Authors:  Marco A Pierotti; Elena Tamborini; Tiziana Negri; Sabrina Pricl; Silvana Pilotti
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

4.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

5.  Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis.

Authors:  Emina E Torlakovic; Nurija Bilalovic; Jahn M Nesland; Goran Torlakovic; Vivi A Flørenes
Journal:  Mod Pathol       Date:  2004-11       Impact factor: 7.842

6.  Expression of E1AF, an ets-oncogene transcription factor, highly correlates with malignant phenotype of malignant melanoma through up-regulation of the membrane-type-1 matrix metalloproteinase gene.

Authors:  Hironobu Hata; Tetsuya Kitamura; Fumihiro Higashino; Kyoko Hida; Koichi Yoshida; Yoichi Ohiro; Yasunori Totsuka; Yoshimasa Kitagawa; Masanobu Shindoh
Journal:  Oncol Rep       Date:  2008-05       Impact factor: 3.906

7.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

Authors:  Rohit Mehra; Scott A Tomlins; Jianjun Yu; Xuhong Cao; Lei Wang; Anjana Menon; Mark A Rubin; Kenneth J Pienta; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

8.  Expression of the ets-1 proto-oncogene in melanocytic lesions.

Authors:  Connie A Keehn; Bruce R Smoller; Michael B Morgan
Journal:  Mod Pathol       Date:  2003-08       Impact factor: 7.842

9.  The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma.

Authors:  T Rothhammer; J C Hahne; A Florin; I Poser; F Soncin; N Wernert; A-K Bosserhoff
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

10.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.

Authors:  Ping Chi; Yu Chen; Lei Zhang; Xingyi Guo; John Wongvipat; Tambudzai Shamu; Jonathan A Fletcher; Scott Dewell; Robert G Maki; Deyou Zheng; Cristina R Antonescu; C David Allis; Charles L Sawyers
Journal:  Nature       Date:  2010-10-03       Impact factor: 49.962

View more
  8 in total

1.  COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.

Authors:  Yuanyuan Xie; Zhen Cao; Elissa Wp Wong; Youxin Guan; Wenfu Ma; Jenny Q Zhang; Edward G Walczak; Devan Murphy; Leili Ran; Inna Sirota; Shangqian Wang; Shipra Shukla; Dong Gao; Simon Rv Knott; Kenneth Chang; Justin Leu; John Wongvipat; Cristina R Antonescu; Gregory Hannon; Ping Chi; Yu Chen
Journal:  J Clin Invest       Date:  2018-03-05       Impact factor: 14.808

Review 2.  ETS factors in prostate cancer.

Authors:  Cheng Qian; Dan Li; Yu Chen
Journal:  Cancer Lett       Date:  2022-01-14       Impact factor: 8.679

3.  ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors.

Authors:  Bo Gun Jang; Hee Eun Lee; Woo Ho Kim
Journal:  Virchows Arch       Date:  2015-08-05       Impact factor: 4.064

4.  A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing.

Authors:  Sounak Gupta; Chad M Vanderbilt; Yun-Te Lin; Jamal K Benhamida; Achim A Jungbluth; Satshil Rana; Amir Momeni-Boroujeni; Jason C Chang; Tiffany Mcfarlane; Paulo Salazar; Kerry Mullaney; Sumit Middha; Ahmet Zehir; Anuradha Gopalan; Tejus A Bale; Ian Ganly; Maria E Arcila; Ryma Benayed; Michael F Berger; Marc Ladanyi; Snjezana Dogan
Journal:  J Mol Diagn       Date:  2020-12-05       Impact factor: 5.568

5.  Targeting Pan-ETS Factors Inhibits Melanoma Progression.

Authors:  Lee Huang; Yougang Zhai; Jennifer La; Jason W Lui; Stephen P G Moore; Elizabeth C Little; Sixia Xiao; Adil J Haresi; Candice Brem; Jag Bhawan; Deborah Lang
Journal:  Cancer Res       Date:  2021-02-01       Impact factor: 13.312

6.  Integrated Analysis of the ETS Family in Melanoma Reveals a Regulatory Role of ETV7 in the Immune Microenvironment.

Authors:  Hui Qu; Hui Zhao; Xi Zhang; Yang Liu; Feng Li; Liyan Sun; Zewen Song
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

7.  Cardiac Pressure Overload Decreases ETV1 Expression in the Left Atrium, Contributing to Atrial Electrical and Structural Remodeling.

Authors:  Naoko Yamaguchi; Junhua Xiao; Deven Narke; Devin Shaheen; Xianming Lin; Erik Offerman; Alireza Khodadadi-Jamayran; Akshay Shekhar; Alex Choy; Sojin Y Wass; David R Van Wagoner; Mina K Chung; David S Park
Journal:  Circulation       Date:  2020-11-23       Impact factor: 29.690

8.  miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1.

Authors:  Ronit Cohen; Eyal Greenberg; Yael Nemlich; Jacob Schachter; Gal Markel
Journal:  Oncotarget       Date:  2015-08-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.